Upgrade to SI Premium - Free Trial

Aptevo Therapeutics (APVO)

4.21 -0.18 (4.10%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/6/26)

Latest Headlines

Form 8-K Aptevo Therapeutics Inc. For: Jul 27 July 27, 2026 4:05 PM - SEC Filing Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone July 27, 2026 8:06 AM - StreetInsider Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone July 27, 2026 8:06 AM - StreetInsider Form S-8 Aptevo Therapeutics Inc. July 24, 2026 4:06 PM - SEC Filing Form 8-K Aptevo Therapeutics Inc. For: Jun 29 June 30, 2026 4:05 PM - SEC Filing Aptevo gets $1.5M grant to advance APVO451 cancer therapy June 30, 2026 8:06 AM - StreetInsider Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors June 30, 2026 8:05 AM - StreetInsider Form SCHEDULE 13G Aptevo Therapeutics Inc. Filed by: NIOWAVE, INC. June 22, 2026 12:11 PM - SEC Filing Form 3 Aptevo Therapeutics Inc. For: May 25 Filed by: NIOWAVE, INC. June 22, 2026 11:45 AM - SEC Filing Form 3 Aptevo Therapeutics Inc. For: May 20 Filed by: Janatpour Mary Jo May 28, 2026 8:03 PM - SEC Filing Aptevo Therapeutics names Mary Janatpour as chief scientific officer May 28, 2026 8:05 AM - StreetInsider Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer May 28, 2026 8:05 AM - StreetInsider Form 8-K Aptevo Therapeutics Inc. For: May 25 May 27, 2026 4:06 PM - SEC Filing Aptevo and Niowave form partnership for cancer drug development May 27, 2026 8:05 AM - StreetInsider Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing May 27, 2026 8:05 AM - StreetInsider Form 10-Q Aptevo Therapeutics Inc. For: Mar 31 May 13, 2026 4:16 PM - SEC Filing Form 8-K Aptevo Therapeutics Inc. For: May 13 May 13, 2026 4:06 PM - SEC Filing Aptevo names Jeff Lamothe CEO, reports AML trial progress May 13, 2026 8:07 AM - StreetInsider Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection May 13, 2026 8:07 AM - StreetInsider Form 8-K Aptevo Therapeutics Inc. For: May 06 May 6, 2026 4:09 PM - SEC Filing Aptevo reports 87% clinical benefit rate in frontline AML trial May 6, 2026 8:10 AM - StreetInsider Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 D May 6, 2026 8:09 AM - StreetInsider Full Article List